Sangamo Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Sangamo Therapeutics's estimated annual revenue is currently $108.5M per year.
- Sangamo Therapeutics's estimated revenue per employee is $203,985
- Sangamo Therapeutics's total funding is $93.2M.
- Sangamo Therapeutics's current valuation is $932.3M. (January 2022)
Employee Data
- Sangamo Therapeutics has 532 Employees.
- Sangamo Therapeutics grew their employee count by -3% last year.
Sangamo Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | eTMF Specialist/Veeva Vault Owner | Reveal Email/Phone |
3 | Chief People Officer | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Chief People Officer | Reveal Email/Phone |
6 | VP, Clinical Development, Autoimmune | Reveal Email/Phone |
7 | SVP Technical Operations | Reveal Email/Phone |
8 | VP Business Development & Alliance Management | Reveal Email/Phone |
9 | VP Autoimmune Franchise, Product Development | Reveal Email/Phone |
10 | VP Clinical Development | Reveal Email/Phone |
Sangamo Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Sangamo Therapeutics?
Sangamo BioSciences (Nasdaq: SGMO) develops and markets novel transcription factors capable of regulating genes. The company’s powerful Universal Gene Recognition™ technology enables the engineering of a particular class of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors that can control gene expression, and consequently, cell function
keywords:N/A
$93.2M
Total Funding
532
Number of Employees
$108.5M
Revenue (est)
-3%
Employee Growth %
$932.3M
Valuation
N/A
Accelerator
Sangamo Therapeutics News
Sangamo Therapeutics also posted earnings of ($0.32) per share during the same quarter last year. The firm is expected to report its next...
California biotech Sangamo Therapeutics has given its first doses of an experimental cell therapy. The company is developing a new type of...
Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to...
In return for global commercialization rights, Pfizer will pay $70 million upfront and up to $475 million in milestone payments that encourage both the commercialization of SB-525 and the development of new hemophilia A therapies. With fresh cash in hand and an orphan drug designation, Sangamo ...
Other Companies in Brisbane
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $140.4M | 535 | 16% | N/A |
#2 | $182.6M | 541 | 5% | N/A |
#3 | $35M | 555 | 24% | N/A |
#4 | $173.4M | 555 | 6% | N/A |
#5 | $171.5M | 560 | 10% | N/A |